Abstract
Chromosomal abnormalities (namely 13q, 17p, and 11q deletions) have prognostic implications and are recurrent in chronic lymphocytic leukemia (CLL), suggesting that they are involved in a common pathogenetic pathway; however, the molecular mechanism through which chromosomal abnormalities affect the pathogenesis and outcome of CLL is unknown. To determine whether the microRNA miR-15a/miR-16-1 cluster (located at 13q), tumor protein p53 (TP53, located at 17p), and miR-34b/miR-34c cluster (located at 11q) are linked in a molecular pathway that explains the pathogenetic and prognostic implications (indolent vs aggressive form) of recurrent 13q, 17p, and 11q deletions in CLL. CLL Research Consortium institutions provided blood samples from untreated patients (n = 206) diagnosed with B-cell CLL between January 2000 and April 2008. All samples were evaluated for the occurrence of cytogenetic abnormalities as well as the expression levels of the miR-15a/miR-16-1 cluster, miR-34b/miR-34c cluster, TP53, and zeta-chain (TCR)-associated protein kinase 70 kDa (ZAP70), a surrogate prognostic marker of CLL. The functional relationship between these genes was studied using in vitro gain- and loss-of-function experiments in cell lines and primary samples and was validated in a separate cohort of primary CLL samples. Cytogenetic abnormalities; expression levels of the miR-15a/miR-16-1 cluster, miR-34 family, TP53 gene, downstream effectors cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) and B-cell CLL/lymphoma 2 binding component 3 (BBC3), and ZAP70 gene; genetic interactions detected by chromatin immunoprecipitation. In CLLs with 13q deletions the miR-15a/miR-16-1 cluster directly targeted TP53 (mean luciferase activity for miR-15a vs scrambled control, 0.68 relative light units (RLU) [95% confidence interval {CI}, 0.63-0.73]; P = .02; mean for miR-16 vs scrambled control, 0.62 RLU [95% CI, 0.59-0.65]; P = .02) and its downstream effectors. In leukemic cell lines and primary CLL cells, TP53 stimulated the transcription of miR-15/miR-16-1 as well as miR-34b/miR-34c clusters, and the miR-34b/miR-34c cluster directly targeted the ZAP70 kinase (mean luciferase activity for miR-34a vs scrambled control, 0.33 RLU [95% CI, 0.30-0.36]; P = .02; mean for miR-34b vs scrambled control, 0.31 RLU [95% CI, 0.30-0.32]; P = .01; and mean for miR-34c vs scrambled control, 0.35 RLU [95% CI, 0.33-0.37]; P = .02). A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. This mechanism provides a novel pathogenetic model for the association of 13q deletions with the indolent form of CLL that involves microRNAs, TP53, and ZAP70.
MeSH Terms
Adult
Aged
Chromosome Deletion
Chromosomes, Human, Pair 11/genetics
Chromosomes, Human, Pair 13/genetics
Chromosomes, Human, Pair 17/genetics
Female
Gene Expression Regulation, Neoplastic
Genes, p53/genetics
Humans
Leukemia, Lymphocytic, Chronic, B-Cell/genetics,pathology
Male
MicroRNAs/genetics
Middle Aged
Prognosis
Transcription, Genetic
Tumor Suppressor Protein p53/physiology
ZAP-70 Protein-Tyrosine Kinase/physiology
Chemicals
MicroRNAs
Tumor Suppressor Protein p53
ZAP-70 Protein-Tyrosine Kinase
ZAP70 protein, human
Authors & Affiliations
29 authors, click to expand affiliations / ORCID
Fabbri Muller
Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA.
Bottoni Arianna
Shimizu Masayoshi
Spizzo Riccardo
Nicoloso Milena S
Rossi Simona
Barbarotto Elisa
Cimmino Amelia
Adair Brett
Wojcik Sylwia E
Valeri Nicola
Calore Federica
Sampath Deepa
Fanini Francesca
Vannini Ivan
Musuraca Gerardo
Dell'Aquila Marie
Alder Hansjuerg
Davuluri Ramana V
Rassenti Laura Z
Negrini Massimo
Nakamura Tatsuya
Amadori Dino
Kay Neil E
Rai Kanti R
Keating Michael J
Kipps Thomas J
Calin George A
Croce Carlo M
References (28)
28 references, click to expand
-
Human MicroRNA targets.
PLoS Biol. 2004 Nov;2(11):e363
PMID: 15502875
-
Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.
Mayo Clin Proc. 1994 Apr;69(4):323-8
PMID: 8170175
-
Modulation of microRNA processing by p53.
Nature. 2009 Jul 23;460(7254):529-33
PMID: 19626115
-
Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia.
Cancer Genet Cytogenet. 2005 Jul 1;160(1):27-34
PMID: 15949567
-
Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer. 2006 Apr;6(4):259-69
PMID: 16557279
-
Binding of ZAP-70 to phosphorylated T-cell receptor zeta and eta enhances its autophosphorylation and generates specific binding sites for SH2 domain-containing proteins.
Mol Cell Biol. 1995 Jun;15(6):3171-8
PMID: 7760813
-
Micro RNAs in animal development.
Cell. 2006 Mar 10;124(5):877-81
PMID: 16530032
-
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications.
Leukemia. 2008 Jun;22(6):1095-105
PMID: 18323801
-
MicroRNAs: small RNAs with a big role in gene regulation.
Nat Rev Genet. 2004 Jul;5(7):522-31
PMID: 15211354
-
A clinical staging system for chronic lymphocytic leukemia: prognostic significance.
Cancer. 1977 Aug;40(2):855-64
PMID: 890666
-
Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays.
Blood. 2007 Feb 1;109(3):1202-10
PMID: 17053054
-
MicroRNAs.
Cancer J. 2008 Jan-Feb;14(1):1-6
PMID: 18303474
-
miR-15 and miR-16 induce apoptosis by targeting BCL2.
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
PMID: 16166262
-
Chronic lymphocytic leukemia.
N Engl J Med. 2005 Feb 24;352(8):804-15
PMID: 15728813
-
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
Cancer Res. 2007 Sep 15;67(18):8433-8
PMID: 17823410
-
Genomic aberrations and survival in chronic lymphocytic leukemia.
N Engl J Med. 2000 Dec 28;343(26):1910-6
PMID: 11136261
-
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.
Br J Haematol. 2003 Apr;121(2):287-95
PMID: 12694251
-
Clinical staging of chronic lymphocytic leukemia.
Blood. 1975 Aug;46(2):219-34
PMID: 1139039
-
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.
N Engl J Med. 2005 Oct 27;353(17):1793-801
PMID: 16251535
-
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
PMID: 12434020
-
Prediction of mammalian microRNA targets.
Cell. 2003 Dec 26;115(7):787-98
PMID: 14697198
-
The 13q and 11q B-cell chronic lymphocytic leukaemia-associated regions derive from a common ancestral region in the zebrafish.
Br J Haematol. 2007 Jun;137(5):443-53
PMID: 17488487
-
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
N Engl J Med. 2004 Aug 26;351(9):893-901
PMID: 15329427
-
A genome-wide map of conserved microRNA targets in C. elegans.
Curr Biol. 2006 Mar 7;16(5):460-71
PMID: 16458514
-
MiR-15a and miR-16-1 cluster functions in human leukemia.
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5166-71
PMID: 18362358
-
MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell. 2004 Jan 23;116(2):281-97
PMID: 14744438
-
Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning.
Methods Mol Biol. 2004;265:131-58
PMID: 15103073
-
MicroRNA signatures in human cancers.
Nat Rev Cancer. 2006 Nov;6(11):857-66
PMID: 17060945